IBDEI0RO ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,13664,2)
 ;;=^340521
 ;;^UTILITY(U,$J,358.3,13665,0)
 ;;=V12.55^^90^848^54
 ;;^UTILITY(U,$J,358.3,13665,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13665,1,4,0)
 ;;=4^V12.55
 ;;^UTILITY(U,$J,358.3,13665,1,5,0)
 ;;=5^Hx of Pulmonary Embolism
 ;;^UTILITY(U,$J,358.3,13665,2)
 ;;=^340615
 ;;^UTILITY(U,$J,358.3,13666,0)
 ;;=454.9^^90^848^84
 ;;^UTILITY(U,$J,358.3,13666,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13666,1,4,0)
 ;;=4^454.9
 ;;^UTILITY(U,$J,358.3,13666,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,13666,2)
 ;;=^328758
 ;;^UTILITY(U,$J,358.3,13667,0)
 ;;=271.3^^90^849^11
 ;;^UTILITY(U,$J,358.3,13667,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13667,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,13667,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,13667,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,13668,0)
 ;;=611.1^^90^849^16
 ;;^UTILITY(U,$J,358.3,13668,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13668,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,13668,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,13668,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,13669,0)
 ;;=704.1^^90^849^17
 ;;^UTILITY(U,$J,358.3,13669,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13669,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,13669,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,13669,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,13670,0)
 ;;=251.2^^90^849^30
 ;;^UTILITY(U,$J,358.3,13670,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13670,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,13670,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,13670,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,13671,0)
 ;;=253.2^^90^849^34
 ;;^UTILITY(U,$J,358.3,13671,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13671,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,13671,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,13671,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,13672,0)
 ;;=733.00^^90^849^43
 ;;^UTILITY(U,$J,358.3,13672,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13672,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,13672,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,13672,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,13673,0)
 ;;=278.00^^90^849^40
 ;;^UTILITY(U,$J,358.3,13673,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13673,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,13673,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,13673,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,13674,0)
 ;;=278.01^^90^849^39
 ;;^UTILITY(U,$J,358.3,13674,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13674,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,13674,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,13674,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,13675,0)
 ;;=250.80^^90^849^10
 ;;^UTILITY(U,$J,358.3,13675,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13675,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,13675,1,5,0)
 ;;=5^DM Type II with LE Ulcer
 ;;^UTILITY(U,$J,358.3,13675,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,13676,0)
 ;;=250.00^^90^849^5
 ;;^UTILITY(U,$J,358.3,13676,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13676,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,13676,1,5,0)
 ;;=5^DM Type II Dm W/O Complications
 ;;^UTILITY(U,$J,358.3,13676,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,13677,0)
 ;;=250.40^^90^849^6
 ;;^UTILITY(U,$J,358.3,13677,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13677,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,13677,1,5,0)
 ;;=5^DM Type II Dm with Nephropathy
 ;;^UTILITY(U,$J,358.3,13677,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,13678,0)
 ;;=250.50^^90^849^9
 ;;^UTILITY(U,$J,358.3,13678,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,13678,1,4,0)
 ;;=4^250.50
